Condition: Pulmonary Embolism · Sponsor: Thrombolex, Inc.
To demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment of intermediate risk pulmonary embolism (PE).
This description comes directly from the study's public registry record.
Chris Schultz, BS · 971-506-7552 · cschultz@ecr-inc.com
Craig Dull, MS · 314-315-6264 · cdull@ecr-inc.com
Always discuss trial participation with your own doctor first.
| Honor Health | Scottsdale, Arizona, United States | Recruiting |
| Carondelet St. Joseph's Hospital | Tuscon, Arizona, United States | Recruiting |
| Radiology and Imaging Specialists | Lakeland, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| Profound Research | Hobart, Indiana, United States | Recruiting |
| Community Health | Indianapolis, Indiana, United States | Recruiting |
| Boston Medical Center | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Lahey Hospital & Medical Center | Burlington, Massachusetts, United States | Recruiting |
| North Mississippi Medical Center | Tupelo, Mississippi, United States | Recruiting |
| Dartmouth Hitchcock | Lebanon, New Hampshire, United States | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06433011